Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

DS Stage I Plasma Cell Myeloma

Known as: plasma cell neoplasm, stage I, Stage I Plasma Cell Myeloma, Multiple Myeloma Stage I 
Plasma cell myeloma with all of the following: 1. Hemoglobin greater than 10 g/Dl, 2. Normal serum calcium, 3. Normal bone structure, 4. Low… 
National Institutes of Health

Related topics

Related topics

33 relations
Atypical lymphocyteB lymphoblastB-LymphocytesChromosome 8 deletion
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
In vivo potential of recombinant granulysin against human tumors
9 kDa granulysin is a protein present in the granules of human CTL and NK cells, with cytolytic activity against microbes and… 
Review
2011
Review
2011
Guidelines for supportive care in multiple myeloma 2011
Supportive care plays an increasingly important role in the modern management of multiple myeloma. While modern treatments have… 
2011
2011
Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) imaging of multiple myeloma: initial clinical efficiency results
ObjectivesTo evaluate the effectiveness of the iterative decomposition of water and fat with echo asymmetric and least-squares… 
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Review
2009
Review
2009
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
The serum immunoglobulin-free light chain (FLC) assay measures levels of free κ and λ immunoglobulin light chains. There are… 
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Review
2008
Review
2008
CS 1 , a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Purpose: We generated a humanized antibody, HuLuc63, which specifically targets CS1 (CCND3 subset 1, CRACC, and SLAMF7), a cell… 
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Review
2008
Review
2008
Pathophysiological underpinnings of multiple myeloma progression.
  • S. Jagannath
  • Journal of managed care pharmacy : JMCP
  • 2008
  • Corpus ID: 24245282
BACKGROUND Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in the bone marrow. Myeloma is… 
Highly Cited
2007
Highly Cited
2007
The benefit of using whole‐body, low‐dose, nonenhanced, multidetector computed tomography for follow‐up and therapy response monitoring in patients with multiple myeloma
The objectives of this study were to assess the status and clinical course of patients with multiple myeloma based on the direct… 
Highly Cited
2006
Highly Cited
2006
International uniform response criteria for multiple myeloma
Correction to: Leukemia (2006) 20, 1467–1473. doi:10.1038/sj.leu.2404284 It has been identified by the authors that there was an… 
2006
2006
LEADING ARTICLE International uniform response criteria for multiple myeloma
BGM Durie, J-L Harousseau, JS Miguel, J Blade, B Barlogie, K Anderson, M Gertz, M Dimopoulos, J Westin, P Sonneveld, H Ludwig, G… 
  • table 3
  • table 5
  • table 6
Highly Cited
2003
Highly Cited
2003
Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases
BackgroundTo determine the prognostic value of cell-cycle associated markers in ocular adnexal lymphoma (OAL).MethodsTwo hundred… 
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE